Lead Product(s) : Testosterone Enanthate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma Gained EU-Approval of Testosterone Enantate
Details : Testosterone enantate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in adult males for conditions associated with a deficiency of endogenous testosterone.
Brand Name : Testosterone Enantate Ever Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 19, 2024
Lead Product(s) : Testosterone Enanthate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma gained EU-Approval for Advanced Cancer Treatment
Details : Eribulin EVER Pharma is a microtubule inhibitor which is indicated for the treatment of locally advanced or metastatic breast cancer and unresectable liposarcoma.
Brand Name : Eribulin EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 16, 2024
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma Announces Approval of Testosterone Undecanoate in the EU
Details : Testosterone undecanoate EVER Pharma is an androgen receptor agonist indicated for testosterone replacement therapy in males for conditions associated with a deficiency of endogenous testosterone.
Brand Name : Testosterone Undecanoate EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 13, 2024
Lead Product(s) : Testosterone Undecanoate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma gains EU Marketing Authorization for Trabectedin
Details : EVER Pharma has received the EU-wide marketing authorization of Trabectedin EVER Pharma, which is available in 0.25mg and 1mg vial sizes for treating advanced soft tissue sarcoma and ovarian cancer.
Brand Name : Trabectedin EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 22, 2024
Lead Product(s) : Trabectedin
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Bortezomib
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma receives EU approval for a liquid ready to use Bortezomib formulation
Details : Bortezomib EVER Pharma is a proteasome inhibitor small molecule drug candidate, which is indicated for the treatment of patients with multiple myeloma and mantle cell lymphoma.
Brand Name : Bortezomib EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 09, 2022
Lead Product(s) : Bortezomib
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Azacitidine
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma receives EU marketing authorization for Azacitidine
Details : Azacitidine EVER Pharma is a DNMT1/DNMT3A indicated for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia.
Brand Name : Azacitidine EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 12, 2021
Lead Product(s) : Azacitidine
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma gains EU marketing authorization for value-added Pemetrexed
Details : EVER Pharma has received EU-wide marketing authorization of Pemetrexed EVER Pharma for the treatment of patients with malignant pleural mesothelioma and non-small cell lung cancer.
Brand Name : Pemetrexed EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
December 15, 2020
Lead Product(s) : Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Cabazitaxel,Prednisone
Therapeutic Area : Oncology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
EVER Pharma gains EU marketing authorization for value-added Cabazitaxel
Details : Cabazitaxel EVER Pharma in combination with prednisone or prednisolone is indicated for the treatment of patients with metastatic castration resistant prostate cancer.
Brand Name : Cabazitaxel EVER Pharma
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 21, 2020
Lead Product(s) : Cabazitaxel,Prednisone
Therapeutic Area : Oncology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?
KEY SERVICES
Reset All
Ever Pharma, highly specialized CDMO in producing complex injectables including high potency & controlled substances & suspensions.